Across a production-scale dry-blending suite, the 1:1 molar salt of L-ornithine and alpha-ketoglutarate is used as a low-hygroscopicity alternative to free L-ornithine hydrochloride in amino acid recovery formulations. The salt delivers approximately 47.5% w/w L-ornithine base equivalent and 52.5% w/w alpha-ketoglutarate equivalent on an anhydrous basis, and is pre-sieved through a 500 μm stainless steel screen before charging into a 2000 L double-cone blender with an intensifier bar at 1500 rpm. Blend inclusion is set at 2.0–7.0% w/w, delivering 1.0–3.0 g OKG per 45 g serving, with label assay targets controlled at ±5% of declared content. Compliance for this product class is anchored to FDA 21 CFR Part 111 cGMP, NSF/ANSI 173 Section 8.2, and ISO 22000:2018 Clause 8.5 where export markets require food safety certification. Downstream processing uses a horizontal ribbon blender at 60% volumetric fill and 12–18 rpm for 15 min, followed by stick-pack filling under 45–55% RH to prevent electrostatic separation of the crystalline OKG from low-density silica flow aids. At 7.0% w/w inclusion, bulk density decreases from 0.52 g/cm³ to 0.47 g/cm³ after 10 min blending, requiring fill-volume correction on vertical auger fillers. Terminal product types are single-serve recovery stick packs, 500 g jars, and HPMC capsules containing 250–500 mg OKG per shell.

Neutral-pH ready-to-drink recovery beverages require post-pasteurization injection because the alpha-ketoglutarate carbonyl group can react with free amino groups in whey protein during retort heating. On a pilot-scale plate heat exchanger, OKG is dissolved in a 0.25 M sodium citrate buffer at 20 °C and metered into the cooled product stream after UHT treatment at 140 °C for 4 s. Addition ratio is 0.25–1.0% w/v, equivalent to 2.5–10.0 g·L⁻¹; above 1.2% w/v, a grainy precipitate forms when the beverage contains 8% whey protein isolate and 0.15% calcium chloride. Process order is critical: adding OKG before homogenization at pH 6.8 together with whey protein results in 4.7% irreversible adsorption to protein at 40 °C after 20 min, whereas post-thermal injection reduces this to 0.8%. Dissolved oxygen is sparged with nitrogen to less than 0.5 mg/L because alpha-keto acids are susceptible to oxidative decarboxylation. Compliance is governed by FDA 21 CFR 117 cGMP for food, Codex Alimentarius CXC 1-1969, and ISO 22000:2018. Terminal product types are 330 mL aseptic cartons, 250 mL PET bottles, and laminated sachets for powder-in-bottle variants.

What limits retort-stable enteral formula fortification with L-ornithine alpha-ketoglutarate beyond 6 g·L⁻¹?

Enteral formula manufacturers fortifying ready-to-hang polymeric products use OKG as a source of ornithine for urea cycle support and alpha-ketoglutarate for TCA cycle anaplerosis in catabolic patients. The upper inclusion boundary observed on pilot-scale retort lines is 6.0 g·L⁻¹; when OKG is added at 8.0 g·L⁻¹ to a casein-dominant formula and held at 121 °C for 15 min, HPLC photodiode-array traces show a new peak at 280–320 nm consistent with Maillard-type condensation between the ketone carbon of alpha-ketoglutarate and lysine ε-amino groups. To avoid this degradation product, the addition ratio is held at 3.0–6.0 g·L⁻¹ in the final ready-to-hang product. Batching proceeds in a high-shear bottom-driven mixer at 1400 rpm for 8 min at 40 °C, followed by two-stage homogenization at 150/50 bar and UHT treatment at 140 °C for 4 s instead of retort sterilization where Commission Delegated Regulation (EU) 2016/128 Annex I permits alternative thermal treatment. Final pH is adjusted to 6.4–6.8 with potassium hydroxide because sodium loading is controlled in these formulas; below pH 6.0, alpha-ketoglutaric acid protonation reduces solubility, and above pH 7.2, base-catalyzed degradation of the alpha-keto acid becomes measurable. In-line conductivity at 14–16 mS/cm is used to detect phase separation. Compliance includes ISO 22000:2018 Clause 8.5, Codex Standard STAN 180-1991, and EU Regulation 2016/128. Terminal product types are 1000 mL ready-to-hang aseptic pouches, 200 mL oral sip bottles, and 30 g modular powder sachets reconstituted with water at point of use.

Rotary tablet presses with 27-station turrets compress OKG-containing cores at 20,000–60,000 tablets per hour when the input granulation is engineered for low-fines flow. Direct compression is preferred over wet granulation because the carboxylate groups of alpha-ketoglutarate dissolve in aqueous binder and produce sticky agglomerates during tray drying. A directly compressible grade with median particle diameter 150–250 μm and bulk density 0.62–0.68 g/cm³ is dry-mixed with microcrystalline cellulose and croscarmellose sodium in a bin blender for 15 min. Tablet inclusion is 250–750 mg OKG per 1000 mg core, i.e. 25–75% w/w, with compression force held at 15–25 kN and ejection force monitored at 400–700 N to detect over-lubrication. A precompression force of 4 kN and main compression force of 20 kN are configured to reduce capping; hardness above 150 N at 60 kN/m² compression pressure indicates excessive dwell and leads to edge fracturing. Residual moisture is maintained at 1.5–2.5% LOD; above 3.0% LOD, punch sticking occurs at 60% RH and requires silicon dioxide addition up to 1.0%. Disintegration is tested according to USP-NF General Chapter 2040 in water at 37 °C, with a 30 min limit; friability is evaluated under Ph. Eur. 2.9.7. Compliance anchors include FDA 21 CFR Part 111 cGMP for dietary supplements and ICH Q3D elemental impurity control when pharmacopeial-grade OKG is specified. Terminal product types are 500 mg scored tablets, 750 mg oval tablets, and clear HPMC capsules containing 250 mg or 500 mg OKG.

When post-surgical oral nutrition requires protein-free nitrogen delivery with low osmolality

For post-surgical oral nutrition requiring protein-free nitrogen delivery with low osmolality, low-volume sip feeds are formulated with OKG rather than intact protein or free arginine to reduce osmotic burden while delivering the urea cycle intermediate ornithine and the TCA cycle intermediate alpha-ketoglutarate. The addition ratio in dry modular sachets is 5.0 g per 200 mL reconstituted solution, corresponding to 25 g·L⁻¹; the measured osmolality remains below 250 mOsm·kg⁻¹ because the salt dissociates into two small-molecule ions without contribution from oligosaccharides or intact protein. Reconstitution kinetics are a critical process parameter: at water temperature 15 °C complete dissolution requires 90 s of manual shaking, while at 20 °C it requires 45 s, and incomplete dissolution creates visible floating fines. The gas-flushed sachet line is challenged with 15 s exposure to 30 °C and 50% RH; moisture gain above 0.5% leads to deliquescence at contact points with foil laminate. Compliance is governed by Commission Delegated Regulation (EU) 2016/128 for food for special medical purposes, Codex Standard STAN 180-1991, and FDA 21 CFR 101.9(j) for medical food labeling in the US market. Downstream production uses a nitrogen-purged stick-pack line with residual oxygen below 3%; foil-lined laminate sachets are sealed at 120 °C for 0.5 s dwell. Terminal product types are 10 g and 25 g foil-lined stick packs, plus 200 mL glass bottle liquid concentrate for pharmacy compounding.

Emulsion pH drift and carbomer incompatibility at 0.5% OKG in oil-in-water skin repair creams

OKG is incorporated into oil-in-water cosmetic emulsions at 0.10–0.50% w/w as a water-phase active, but the addition of 0.25% sodium hydroxide after dissolving the salt is required to bring the final pH from 4.1–4.4 into the dermal compatibility window of 5.2–5.8. Carbomer-based rheology modifiers are incompatible at this inclusion because the carboxylate groups of alpha-ketoglutarate compete for counterion binding and collapse the microgel network; Sepinov EMT 10 or hydroxyethylcellulose is used instead. Processing is performed in a vacuum-scale counter-rotating stirrer at 65 °C for the oil phase, cooled to 40 °C before the aqueous OKG solution is added, then homogenized at 3000–5000 rpm for 5–8 min. Accelerated stability at 45 °C for 12 weeks shows 8% loss of alpha-ketoglutarate content when oxygen-barrier packaging is absent; EVOH/PE airless pump packaging reduces loss to 2%. Published data for this specific configuration is limited; formulation work should confirm batch-to-batch pH drift after 4 weeks at 40 °C and 75% RH. Compliance includes Regulation (EC) No 1223/2009, ISO 22716:2007 GMP, and INCI listing as L-Ornithine Alpha-Ketoglutarate. Terminal product types are 30 mL airless pump serums, 50 mL barrier recovery creams, and anhydrous balms containing up to 0.20% w/w OKG.